A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa by Addiss, David G et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Filaria Journal
Open Access Review
A Framework for Decision-Making for Mass Distribution of 
Mectizan® in Areas Endemic for Loa loa
David G Addiss*1, Richard Rheingans2, Nana AY Twum-Danso3 and 
Frank O Richards4
Address: 1U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Rollins School of Public Health, Emory University, Atlanta, GA, 
USA, 3Mectizan® Donation Program, Decatur, GA, USA and 4Global 2000 River Blindness Program, The Carter Center, Atlanta, GA, USA
Email: David G Addiss* - dga1@cdc.gov; Richard Rheingans - rrheing@sph.emory.edu; Nana AY Twum-Danso - ntwumdanso@taskforce.org; 
Frank O Richards - fxr1@cdc.gov
* Corresponding author    
Abstract
Background:  The occurrence of Loa loa encephalopathy following mass treatment of
onchocerciasis with Mectizan® has adversely affected onchocerciasis control efforts in central
Africa. Persons with very high densities of L. loa microfilaremia are at increased risk of
encephalopathy, but little is known about the geographic distribution of these persons within
central Africa. RAPLOA, a new technique that correlates the proportion of community members
reporting a history of eyeworm with the prevalence of high-intensity L. loa microfilaremia in that
community, may be useful for rapid assessment of areas at potential risk of treatment-related L. loa
encephalopathy. Validation of RAPLOA is ongoing. The operational and risk-reduction advantages
of RAPLOA over the current technique of village-by-village rapid epidemiologic assessment for
onchocerciasis (REA) are unknown.
Methods: We developed a decision model to compare four strategies for minimizing sequelae of
L. loa encephalopathy following mass treatment with Mectizan®  in areas co-endemic for
onchocerciasis and loiasis: REA; RAPLOA with threshold eyeworm prevalences of 40% and 20%
(RAPLOA-40 and RAPLOA-20, respectively); and combined REA/RAPLOA-40.
Results:  I n  t h e  m o d e l ,  a l l  f o u r  s t r a tegies significantly reduced risk of death and neurologic
complications from L. loa encephalopathy, but RAPLOA-20 and REA resulted in half as many such
cases as did RAPLOA-40 or combined REA/RAPLOA-40.
Conclusion:  RAPLOA is likely to be useful programmatically in reducing risk of L. loa
encephalopathy following mass treatment with Mectizan®. It also may be cost-saving. Before full-
scale implementation, additional data are needed on geographic clustering of high-density L. loa
microfilaremia and on RAPLOA's reliability and cost.
Background
For more than a decade, mass distribution of Mectizan®
(ivermectin, MSD) has been recommended for prevention
of blindness caused by infection with Onchocerca volvulus.
The remarkable efficacy of Mectizan® against the micro-
filariae of O. volvulus, as well as the safety and effectiveness
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of the drug against a broad range of intestinal helminths
and ectoparasites, has resulted in its acceptance at the
community level. However, in recent years, serious
adverse events (SAEs) associated with mass distribution of
Mectizan® in Cameroon have caused widespread concern.
Many of these SAEs were characterized by progressive neu-
rologic decline and encephalopathy within a few days of
taking Mectizan®  [[1,2], Mectizan®  Donation Program
(MDP), unpublished data]. Affected persons lived in loia-
sis-endemic areas and, based on their post-treatment L. loa
microfilarial loads, are presumed to have had high densi-
ties of L. loa microfilaremia prior to treatment with
Mectizan® (MDP, unpublished data).
The Mectizan® Expert Committee (MEC) limits mass dis-
tribution of Mectizan® to areas considered meso- or hyper-
endemic for onchocerciasis, as determined by the tech-
nique known as rapid epidemiologic mapping for
onchocerciasis (REMO) [3]. REMO is based on rapid epi-
demiologic assessment (REA) for the presence of
onchocercal nodules in samples of 30 adult men in
selected indicator villages. Villages with a nodule preva-
lence of ≥ 40%, 20–39%, or <20% are defined as hyper-,
meso-, or hypo-endemic, respectively. These estimates of
onchocerciasis endemicity are projected onto larger geo-
graphical areas with similar ecologic characteristics [4].
Although residents of areas classified as hypo-endemic do
not receive mass treatment with Mectizan®, they are eligi-
ble for individual clinic-based treatment if they are diag-
nosed with onchocerciasis.
REMO projections sometimes result in the inclusion of
hypo-endemic villages into areas designated for mass dis-
tribution of Mectizan®. Until recently, such misclassifica-
tions of hypo-endemic villages had few, if any, known
negative consequences. Individuals living in these villages
benefited from Mectizan®'s action against intestinal
helminths and ectoparasites, even if few of them suffered
from onchocercal skin or eye disease. However, when
cases of L. loa encephalopathy occurred following mass
distribution of Mectizan®, the specificity of REMO (i.e. its
ability to exclude hypo-endemic villages from mass drug
distribution) was no longer considered adequate.
During the mid-1990s, reviews of the clinical features of
Mectizan®-associated L. loa encephalopathy revealed that
basic supportive care (i.e., hydration, feeding, and nursing
care) was critical for patient recovery; indeed, prompt and
sustained supportive care is the most important therapeu-
tic measure [5]. Thus, mass distribution of Mectizan® in L.
loa-endemic areas should be preceded by community edu-
cation to increase awareness of possible SAEs following
treatment. During and after mass drug distribution, inten-
sified surveillance for SAEs is required, as is a referral sys-
tem to appropriate health facilities for any SAEs that may
occur [5]. In affected areas, these requirements have led to
a temporary shift away from the strategy of community-
directed treatment with ivermectin (CDTI) currently
favored by the African Programme for Onchocerciasis
Control (APOC). CDTI emphasizes community decision-
making on the timing and manner of drug distribution by
community volunteers (rather than by nurses or other
medical personnel) [6,7].
In 2000, the MEC and the Technical Consultative Com-
mittee (TCC) of APOC recommended a new approach to
mass treatment for onchocerciasis in areas co-endemic for
loiasis. This approach begins with an environmental risk
model based on remote sensing data for Central and West
Africa. The model, developed by Madeleine Thomson and
colleagues at the Liverpool School of Tropical Medicine,
predicts the prevalence of L. loa infection based on vegeta-
tion and other land characteristics associated with a suita-
ble environment for the presence of Chrysops spp., the
vector of L. loa [8]. The model generates a map that,
although still in the process of being validated, serves as
an important operational starting point when considering
whether a given area is likely to be endemic for loiasis [9].
For high-risk areas on the map, the MEC/TCC recommen-
dations for areas co-endemic for onchocerciasis and loia-
sis currently require village-by-village REA before
initiating mass treatment with Mectizan® [3,9]. Mass dis-
tribution of Mectizan® is recommended for all villages that
remain classified as meso- or hyper-endemic for
onchocerciasis by REA – but only after enhanced health
education and training of community members, and only
if SAE surveillance by community distributors and medi-
cal preparedness for SAE management can be ensured. In
villages confirmed as hypo-endemic on the basis of REA,
mass treatment is not recommended, although Mectizan®
is made available to treat individuals with clinical
onchocerciasis after health workers assess the individual's
burden of L. loa microfilariae and related risk of L. loa
encephalopathy.
This policy has financial and logistical implications.
Increased costs result from village-by-village REA before
treatment, as well as from safeguards required to reduce
risk of death and disability from L. loa encephalopathy in
hyper- and meso-endemic areas. Further, communities
classified as hypo-endemic may be surrounded by meso-
and hyper-endemic communities, and this can complicate
the public health messages and interventions in both
areas.
The current MEC/TCC approach assumes maximum risk
of L. loa encephalopathy in all areas predicted as high risk
on the environmental risk model map, and it uses village-
by-village REA to increase programmatic certainty that
"enough" onchocerciasis exists to warrant mass treatmentFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S9
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with Mectizan®. This strategy focuses the mass treatment
decision on the health benefits of preventing blindness
rather than on the risk of L. loa encephalopathy following
treatment. It was adopted because the only way to reliably
predict risk of encephalopathy was to microscopically
examine blood samples from all residents of a treatment
area for L. loa microfilaremia before mass treatment.
Operationally, this was thought to be difficult in remote
parts of rural Africa.
A new technique, known as RAPLOA, has been developed
that does not require collection of blood to detect areas
with high-density L. loa microfilaremia [10]. A recent
multi-center study showed that 1) the prevalence of L. loa
infection is associated with microfilarial density; and 2)
the prevalence of individuals with high-level micro-
filaremia in a community is associated with the percent-
age of community members who respond positively to
questions about previous experience with a migrating eye-
worm [11]. This study found that the most sensitive and
specific rapid assessment tool was based on a "restricted"
definition of eyeworm passage, in which the subject must
recognize a photograph of eyeworm as the same condi-
tion that he or she had experienced, and the eyeworm epi-
sode must have lasted no more than 7 days. In three
different ecologic settings in Nigeria and Cameroon,
investigators found that the prevalence of persons with
high microfilarial densities (≥30,000 microfilariae per
milliliter [mf/ml] of blood) remained low when the prev-
alence of a history of eyeworm was less than 40%, but that
it increased rapidly above this level (Figure 1, excerpted
from the multi-country report on RAPLOA [10]).
RAPLOA is now being suggested as an alternate approach
to REA in areas that are predicted by the environmental
risk model map to be co-endemic for L. loa. Conceptually,
such an approach, which bases the mass treatment deci-
sion on a defined risk of L. loa encephalopathy following
Mectizan®  treatment, seems more appealing than one
based solely on an assessment of how much onchocercia-
sis is "enough" at the village level to justify an unknown
risk of treatment-related L. loa encephalopathy. A thresh-
old of 40% of persons with a history of eyeworm has been
suggested for distinguishing between high-risk areas for L.
loa encephalopathy (which would require enhanced com-
munity education, SAE surveillance, and supportive med-
ical care) from those at low risk [10,11]. Presumably, the
traditional CDTI approach to mass drug distribution
could be used in areas categorized as low risk. We refer to
RAPLOA based on a 40% threshold of eyeworm preva-
lence as RAPLOA-40.
Data on the sensitivity and specificity of RAPLOA are cur-
rently limited. A close examination of Figure 1 reveals that
in some villages where <40% of persons have a history of
eyeworm, as many as 2% of persons also have L. loa
microfilarial densities of ≥30,000 per ml. These persons
would be at risk of L. loa encephalopathy if mass distribu-
tion of Mectizan® were implemented. Use of 20% preva-
lence of a history of eyeworm as the threshold (RAPLOA-
20) would substantially reduce (to near zero, based on
Figure 1) the prevalence of persons with microfilarial den-
sities of ≥30,000 per ml in areas classified as low risk.
Another alternative, suggested by some, would be to apply
both REA and RAPLOA-40 simultaneously in a given area
to gather the maximum available information about both
onchocerciasis and loiasis. With this strategy, once com-
munities are confirmed by REA as hyper- or meso-
endemic for onchocerciasis, RAPLOA-40 would be used to
determine whether they are at high risk for L. loa enceph-
alopathy following treatment with Mectizan®.
Rationale for a decision analysis model
Decision models can be useful to guide programmatic
decisions, identify new research needs, identify critical
decision points, and determine factors that most strongly
influence both cost and safety. The primary purpose of the
current model is to provide a structured framework to
understand and estimate the potential health risks and
benefits of alternative approaches to mass treatment strat-
egies in areas that are co-endemic for onchocerciasis and
Prevalence of persons with L. loa microfilaremia ≥ 30,000 per  ml as a function of the prevalence of a restricted definition of  eyeworm, from Figure 10 of the multi-center report on  RAPLOA [10] Figure 1
Prevalence of persons with L. loa microfilaremia ≥ 30,000 per 
ml as a function of the prevalence of a restricted definition of 
eyeworm, from Figure 10 of the multi-center report on 
RAPLOA [10]. See RAPLOA in the List of Abbreviations for 
details on the restricted definition of eyeworm.
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loiasis. The broad conceptual framework underlying the
model, described above, is shown graphically in Figure 2.
The underlying assumptions of the model are based on
the scientific literature and, when scientific data are lack-
ing, on expert opinion and information available to the
MDP (See additional file 1: Assumptions used in the deci-
sion model).
Methods
The model was constructed in the standard fashion using
TreeAge software (Williamstown, MA). Four strategies
(REA, RAPLOA-40, RAPLOA-20, and combined REA/
RAPLOA-40) were examined (Figure 3) under four differ-
ent ecologic conditions with varying intensities of O. vol-
vulus and L. loa transmission (Appendix - see additional
file 1). We examined three principal outcomes: 1)
onchocercal blindness; 2) chronic neurologic complica-
tions or death associated with L. loa encephalopathy fol-
lowing Mectizan® treatment; and 3) disability-adjusted
life years (DALYs), which were influenced by onchocercal
blindness and skin disease as well as by treatment-related
L. loa encephalopathy, death, and chronic neurologic
sequelae (Appendix - see additional file 1) [12]. DALY
losses for onchocercal blindness and skin disease were
extrapolated from the Global Burden of Disease estimates
(Appendix - see additional file 1) [12]. No similar esti-
mates are available for Loa loa-related events. As a result,
authors' estimates were used to reflect a short-term serious
event (L. loa encephalopathy), a chronic severe event (per-
manent neurologic sequelae), and death at unknown age.
Economic outcomes, particularly the costs associated with
the various approaches, were not included because data
were not available.
Risk of L. loa encephalopathy following Mectizan® 
treatment
The risk of L. loa encephalopathy temporally related to
Mectizan® treatment was assumed to be a function of a
Conceptual framework for current and alternative approaches to minimizing risks and maximizing benefits of mass treatment  with Mectizan® in areas suspected of being co-endemic for onchocerciasis and loiasis Figure 2
Conceptual framework for current and alternative approaches to minimizing risks and maximizing benefits of mass treatment 
with Mectizan® in areas suspected of being co-endemic for onchocerciasis and loiasis. Implementation of training, surveillance, 
and supportive care, indicated in shaded boxes, are assumed to reduce the risk of death associated with SAEs. + indicates the 
condition indicated -indicates the absence of the condition.
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threshold prevalence of high intensity microfilaremia,
defined as 30,000 mf/ml of blood. This threshold was
suggested previously by Ducorps and colleagues [1] and
Boussinesq and co-workers [13]. Other investigators have
suggested thresholds as high as 50,000 mf/ml [2] and as
low as 10,000 mf/ml [5]. We assumed that the risk of L.
loa  encephalopathy following Mectizan® treatment was
reduced by 50% in the second year of treatment.
The estimated risk of L. loa encephalopathy following
Mectizan® treatment is based on two factors: 1) the per-
centage of communities with different portions of their
population having microfilarial loads of ≥30,000 mf/ml
(which we categorized as 0%, 0.1–0.9%, 1.0–1.9%, 2.0–
3.9%, 4.0–7.9%, and ≥ 8%); and 2) risk of L. loa enceph-
alopathy following Mectizan® treatment in individuals
with microfilarial loads above the 30,000 mf/ml thresh-
Decision model of four strategies to reduce risk of L. loa encephalopathy following treatment with Mectizan® in areas that are  1) thought to be endemic for loiasis on the basis of remote sensing (the environmental risk model map); and 2) determined to  be hyper- or meso-endemic for onchocerciasis by REMO Figure 3
Decision model of four strategies to reduce risk of L. loa encephalopathy following treatment with Mectizan® in areas that are 
1) thought to be endemic for loiasis on the basis of remote sensing (the environmental risk model map); and 2) determined to 
be hyper- or meso-endemic for onchocerciasis by REMO. Abbreviations: oncho = onchocerciasis; Rx = treatment. Additional 
details on the model are available from the authors upon request. [+] indicates truncation of a branch to simplify the figure. For 
the remainder of this branch, see the structure of similarly labelled branches elsewhere in the figure.
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old, which we assumed to be 1% (Appendix - see addi-
tional file 1). The model estimates the prevalence of
individuals with microfilarial loads of ≥30,000 mf/ml
within communities that receive 1) mass treatment with-
out additional education or enhanced SAE surveillance; 2)
mass treatment with additional education and enhanced
surveillance; or 3) clinic-based treatment for individuals
diagnosed with onchocerciasis. These estimates are based
on the estimated sensitivity and specificity of RAPLOA
(Figure 1), the performance of REA, and the underlying
distribution of high-intensity L. loa microfilaremia within
communities (Appendix - see additional file 1). Four sce-
narios of varying L. loa prevalence were examined, two in
which 60% of communities had ≥ 1 resident with high-
density L. loa microfilaremia and two in which this figure
was 10% (Appendix - see additional file 1).
Based on the estimated prevalence of individuals with
high intensity infection, the community risk of L. loa
encephalopathy following Mectizan®  treatment was
estimated. Three ultimate outcomes were considered:
death, chronic or permanent neurological damage, and
no adverse outcome. We assumed that the outcome of L.
loa  encephalopathy following Mectizan® treatment was
influenced by the presence or absence of adequate sup-
portive care for these patients (Appendix - see additional
file 1).
Risk of Onchocerciasis
The model assumes that the lifetime risk of onchocercal
blindness and skin disease is determined by the estimated
community prevalence of onchocerciasis as determined
by REA. In areas where the sowda form of onchocerciasis
predominates, this assumption would underestimate risk
of skin disease. In the high-prevalence scenarios for O. vol-
vulus, the percentage of communities that were classified
as hyper-, meso- and hypo-endemic for onchocerciasis
was 60%, 30%, and 10%, respectively. For low-prevalence
areas, these figures were 30%, 30% and 40%, respectively
(Appendix - see additional file 1).
Since treatment halts progression of disease in those who
already have clinical manifestations and prevents disease
manifestations in those already infected or those not yet
infected, we assumed that treatment is completely effec-
tive in eliminating the risk of morbidity due to onchocer-
ciasis among treated individuals. We assumed that there
was no impact of mass distribution on transmission or on
risk of blindness or skin disease among persons who did
not take Mectizan®. Thus, non-treated individuals were
assumed to receive no benefit from mass treatment in
their village. Drug coverage was considered to be system-
atic and to remain constant at 65%.
Results
Health benefits of Mectizan® treatment (DALYs and 
reduction in blindness)
In our model, onchocerciasis reduced average disability
adjusted life years (DALYs) by 1.52 and 0.88 years per per-
son in the high- and low-prevalence areas, respectively
(Table 1). Although our model was conservative in assum-
ing systematic annual drug coverage of only 65%, mass
treatment with Mectizan® resulted in a net gain of 0.5 to
1.0 DALYs per person (reducing lost DALYs from 1.52 to
0.53 and from 0.88 to 0.31 in high - and low - prevalence
areas, respectively), even in the absence of measures to
reduce the risk of L. loa-associated death and permanent
disability (Table 1).
Similarly, in our model, mass treatment with Mectizan®
reduced the lifetime risk of blindness from 166 to 58 cases
per 1000 population in areas with a high prevalence of
onchocerciasis and from 94 to 33 cases per 1000 popula-
tion in low prevalence areas. Because REA-based strategies
to reduce Mectizan®-related L. loa encephalopathy result
in fewer people receiving Mectizan®, these reductions in
Table 1: Estimated mean disability-adjusted life years (DALYs) lost on a per-capita basis as a result of onchocercal blindness, skin 
disease, and L. loa encephalopathy, under conditions of: 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction 
strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa 
encephalopathy. DALYs are expressed as mean years lost per person for the entire population. Four scenarios are considered based on 
high and low prevalence of loiasis and onchocerciasis, respectively (as defined in the Appendix - see additional file 1).
Loiasis Prevalence High High Low Low
Onchocerciasis Prevalence High Low High Low
No Mectizan® treatment 1.5155 0.8822 1.5155 0.8822
Mectizan® treatment
No risk reduction strategy 0.5319 0.3102 0.5309 0.3092
REA 0.5393 0.3436 0.5391 0.3436
RAPLOA-40 0.5307 0.3090 0.5305 0.3088
RAPLOA-20 0.5305 0.3088 0.5305 0.3088
REA/RAPLOA-40 0.5341 0.3228 0.5313 0.3124Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S9
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blindness were somewhat diminished in the presence of
such strategies (Table 2).
Reduction in L. loa associated SAEs
In the absence of any approach to reduce complications of
L. loa encephalopathy following mass treatment with
Mectizan®, the estimated risk of L. loa associated death or
permanent neurologic sequelae was 85.1 and 26.0 cases
per 1 million population in high- and low-prevalence
areas for loiasis, respectively. All four risk-reduction strat-
egies dramatically reduced the risk of these complications
(Table 3). Regardless of the prevalence of onchocerciasis
or loiasis, the current risk reduction strategy, REA, led to
the greatest reductions (94% – 99%) in death and perma-
nent disability associated with L. loa encephalopathy.
Similar reductions (93–98%) were observed for RAPLOA-
20. RAPLOA-40 and the combined REA/RAPLOA-40
approach were less effective in reducing risk (Table 3, Fig-
ure 4). Risk of L. loa associated death and disability was
2.0 to 6.7 times greater with RAPLOA-40 or REA/
RAPLOA-40 than with REA or RAPLOA-20 (Table 3).
Figure 4 illustrates the relationship between the estimated
number of cases of blindness and the number of deaths
and chronic disabilities resulting from L. loa encephalop-
athy in the context of 1) no mass treatment; 2) mass treat-
ment with no risk reduction strategies; and 3) mass
treatment with each of the four risk reduction strategies in
the model.
Discussion
The occurrence of L. loa encephalopathy following mass
treatment with Mectizan®  has negatively affected
onchocerciasis control efforts in central Africa, which rely
on a strategy of mass treatment with Mectizan® using
CDTI. The lack of a rapid epidemiologic assessment tool
to estimate risk of L. loa encephalopathy following Mecti-
zan® treatment has severely limited attempts to expand
onchocerciasis control into areas thought to be co-
endemic for L. loa. RAPLOA could represent a significant
advance in this regard. Validation of RAPLOA is currently
ongoing and discussions are now underway about how
best to apply RAPLOA programmatically to reduce risk of
treatment-related  L. loa encephalopathy and its
complications.
Our model showed the substantial public health benefits
of Mectizan® distribution, expressed either as DALYs or as
blindness prevention, even in areas with co-endemic loia-
sis in which no measures to reduce L. loa associated risk
were implemented. The model also indicated that all four
risk-reduction strategies would substantially decrease the
risk of death and permanent disability from L. loa enceph-
alopathy temporally related to Mectizan® treatment (Fig-
ure 4). However, among the four strategies, differences
were noted. Two approaches – the currently
recommended REA and RAPLOA-20 – resulted in the
greatest reductions in death and permanent disability
from L. loa encephalopathy. In comparison, risk of death
and permanent disability was about twice as high for the
strategy based on RAPLOA-40. We found no advantage to
a strategy that would employ a combination of REA and
RAPLOA-40.
The currently recommended approach for reducing risk of
death and permanent neurologic complications from L.
loa encephalopathy incurs significant programmatic costs.
These costs result from village-by-village assessments of
onchocerciasis endemicity by REA, as well as the need to
1) educate at-risk communities about L. loa encephalopa-
thy, 2) establish surveillance for treatment-related SAEs,
and 3) provide appropriate supportive medical and nurs-
ing care for those who develop L. loa encephalopathy fol-
lowing mass treatment. Community education,
surveillance, and supportive medical care are key elements
in all four risk-reduction strategies evaluated in our
model. Village-by-village RAPLOA would likely take
about as long to execute as REA and would consume com-
parable financial and human resources. Data on the geo-
Table 2: Estimated risk of blindness per 1000 population in four scenarios based on high and low prevalence of loiasis and onchocerciasis, 
under conditions of: 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass treatment 
using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy.
Loiasis Prevalence High High Low Low
Onchocerciasis Prevalence High Low High Low
No Mectizan® treatment 166.0 94.0 166.0 94.0
Mectizan® treatment
No risk reduction strategy 58.1 32.9 58.1 32.9
R E A 5 8 . 73 5 . 55 8 . 73 5 . 5
R A P L O A - 4 0 5 8 . 13 2 . 95 8 . 13 2 . 9
R A P L O A - 2 0 5 8 . 13 2 . 95 8 . 13 2 . 9
REA/RAPLOA-40 58.4 33.9 58.2 33.3Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S9
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graphic distribution of high-intensity L. loa
microfilaremia are limited. Thus, it is not yet certain that
the results from a RAPLOA assessment in a small sample
of villages would accurately predict the risk of SAEs
throughout an entire area. In the absence of such a sam-
pling scheme, village-by-village assessment using
RAPLOA would be necessary and would likely provide no
significant cost savings over village-by-village REA.
If RAPLOA is validated and found to be operationally
reproducible and feasible, however, it would offer several
advantages. Data collected through RAPLOA could signif-
icantly enhance our understanding of the epidemiology of
high-density L. loa microfilaremia and provide an oppor-
tunity to refine the predictions of the environmental risk
model map. The current approach of REA assumes that
the map is 100% accurate in identifying areas that are
highly endemic for loiasis. In these areas, onchocerciasis
Table 3: Estimated risk of death or chronic disability per 1 million population resulting from L. loa encephalopathy following mass 
treatment with Mectizan®, under conditions of: 1) no mass treatment; 2) mass treatment with no risk reduction strategy; and 3) mass 
treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy. Four scenarios 
are considered based on high and low prevalence of loiasis and onchocerciasis, respectively (defined in the Appendix - see additional file 
1).
Loiasis Prevalence High High Low Low
Onchocerciasis Prevalence High Low High Low
No Mectizan® t r e a t m e n t 0000
Mectizan® treatment
No risk-reduction strategy 85.1 85.1 26.0 26.0
REA 5.1 3.4 0.5 0.3
RAPLOA-40 12.9 12.9 2.0 2.0
RAPLOA-20 5.6 5.6 0.6 0.6
REA/RAPLOA-40 12.4 11.0 2.0 1.9
Estimated rates of lifetime blindness (per 1000 population) and of death and chronic disability from L. loa encephalopathy,  under conditions of 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass  treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 Figure 4
Estimated rates of lifetime blindness (per 1000 population) and of death and chronic disability from L. loa encephalopathy, 
under conditions of 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass 
treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40. Data are shown for two levels of loiasis co-
endemicity, both with highly endemic onchocerciasis. Similar patterns are observed in areas of low onchocerciasis endemicity 
(data not shown).
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control programs are required invariably to carry out REA
in every village and, in all villages where mass treatment
with Mectizan® is offered, to bear the additional costs of
enhanced training, SAE surveillance, and reinforcing
health systems for the clinical management of L. loa
encephalopathy. However, the environmental risk model
map predicts risk of loiasis on the basis of environmental
features that indicate favorable habitat for the Chrysops
vector. It is possible (and likely) that many areas condu-
cive to the vector do not have significant transmission of
L. loa. Use of RAPLOA may reveal the absence of high-den-
sity L. loa microfilaremia (as predicted by history of eye-
worm) throughout much of central Africa where the
environmental risk model map currently predicts L. loa to
be highly endemic. In these areas, mass treatment with
Mectizan® could be instituted with no need for enhanced
SAE training, surveillance, and medical systems. This
would result in large cost savings at the regional level and
vastly simplified program operations. Because the actual
prevalence of high-density L. loa microfilaremia through-
out much of central Africa is unknown and cost data were
not available, we could not account for these potential
advantages of RAPLOA in the decision model. Finally, the
RAPLOA approach may prove useful in the Global Pro-
gramme to Eliminate Lymphatic Filariasis for assessing
risk of treatment-related L. loa encephalopathy in areas
that are co-endemic for L. loa and Wuchereria bancrofti. In
most of sub-Saharan Africa, this programme relies on
mass treatment with both Mectizan®  and albendazole
[14].
A major challenge to all four risk-reduction strategies is
the potential for misclassification, which may be substan-
tial. Unfortunately, the cost of being able to rapidly detect
and treat all cases of L. loa encephalopathy temporally
related to Mectizan® treatment appears to be the establish-
ment of surveillance and medical systems that, in many
areas, may be unnecessary. The principal disadvantage of
RAPLOA-20 is its relatively low specificity, which could
result in large areas of central Africa being misclassified as
high risk for L. loa encephalopathy and unnecessary
expenditures of health resources. Because RAPLOA-40 is
more specific, its use would avoid many of these unneces-
sary costs. However, our model suggests that RAPLOA-40
could result in twice as many L. loa associated deaths and
cases of chronic disability, because this technique allows
communities classified as low risk to have as many as 2%
of persons with ≥30,000 L. loa mf/ml blood. These com-
munities could therefore receive Mectizan® in the absence
of adequate surveillance and systems to rapidly detect and
treat L. loa encephalopathy. The magnitude of this prob-
lem would depend on the degree to which communities
with persons at risk for L. loa encephalopathy are geo-
graphically clustered within areas classified as high risk by
RAPLOA-40. If they are not tightly clustered, but rather
scattered in relatively small numbers throughout central
Africa, Mectizan®-related L. loa encephalopathy will be dif-
ficult to predict and even harder to prevent. The apparent
clustering of reported cases of L. loa encephalopathy in
certain regions of Cameroon is a reassuring sign in this
regard. Further research on the performance of RAPLOA
and on the geographic clustering of communities with
persons with high microfilarial loads is urgently needed.
As with any decision model, the accuracy of our conclu-
sions is limited by the uncertainty surrounding our
assumptions. For many of our assumptions, published
data are lacking and we relied on expert opinion and
unpublished data available to the MDP. Even when data
were available, especially on the epidemiology and health
risks of L. loa, they were limited to a few studies in specific
areas; the degree to which these data are representative for
other areas in central Africa is not known. When we per-
formed sensitivity analyses for the key variables in our
model, our basic conclusions did not substantially change
(data not shown).
Our decision model significantly underestimates the
health benefits of Mectizan®. We considered as treatment-
related benefits only prevention of onchocercal blindness
and skin disease, and omitted benefits resulting from
Mectizan®'s action against intestinal helminths, Strongy-
loides stercoralis,  Wuchereria bancrofti, and a variety of
ectoparasites. Our assumption that drug coverage was
65% is consistent with population-based coverage figures
reported from onchocerciasis control programs in Africa.
However, by assuming that this coverage was systematic,
35% of persons in affected communities would never
have received Mectizan®. This assumption limited both
the health benefits of Mectizan® and the number of per-
sons with L. loa-associated encephalopathy. In a sensitiv-
ity analysis that assumed a random coverage pattern, with
up to 100% of those targeted for mass treatment receiving
one or more doses of Mectizan®, the conclusions of our
model did not change. The relative effectiveness of each of
the four strategies in reducing onchocercal blindness and
the risk of L. loa associated death and disability remained
constant (data not shown).
Conclusion
In central Africa where onchocerciasis and loiasis are co-
endemic, L. loa encephalopathy has occurred following
mass treatment with Mectizan®. In some cases, this has
resulted in death or chronic disability. A new rapid assess-
ment technique called RAPLOA may provide programme
managers with an important tool with which to assess L.
loa  endemicity and the risk of treatment-related L. loa
encephalopathy. Our decision model suggests that use of
RAPLOA-20 or the current approach of REA would lead to
the greatest reductions in death and permanent disabilityFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S9
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associated with L. loa encephalopathy. However, use of
REA would result in fewer communities receiving Mecti-
zan®. Compared to REA, the usefulness of RAPLOA, both
in preventing blindness and avoiding L. loa encephalopa-
thy following Mectizan® treatment in co-endemic areas, is
highly dependent on the RAPLOA cutoff point. Full
programmatic implementation of RAPLOA will require
testing of the method in other areas of central Africa, an
improved understanding of geographic clustering of high-
density  L. loa microfilaremia, sampling strategies that
would avoid the need for RAPLOA assessments in all com-
munities, cost analyses, and confirmation that the ques-
tionnaire can be administered easily and reliably by field
staff.
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